HER2 Biomarkers
News and reporting on HER2 biomarkers.
Seagen Going After Tukysa, Herceptin Combo Approval in HER2-Positive Colorectal Cancer
The company plans to seek accelerated approval for the regimen after seeing a 38 percent objective response rate in the MOUNTAINEER trial.
FDA Approves Enhertu as Second-Line Therapy for Advanced HER2-Positive Breast Cancer
The regulatory action converts the accelerated approval for AstraZeneca and Daiichi Sankyo's drug to full approval and makes it a second-line option.
Trial data and real-world evidence support treatment combos with Novartis' Kisqali and Pfizer's Ibrance, respectively, for HR-positive, HER2-negative breast cancer.Â
Medac, Byondis Strike Commercialization Pact for HER2-Targeted Antibody-Drug Conjugate
Byondis is hoping to launch the agent, SYD985, in the UK and EU as a treatment for HER2-positive advanced breast cancer.
AstraZeneca Q1 Oncology Product Sales Increase 14 Percent Led by Tagrisso
Revenues from AstraZeneca's oncology segment in Q1 2022 totaled $3.64 billion, comprising around a third of the company's total revenues.